Literature DB >> 26101897

Cell cycle and dystrophin dysregulation in GIST.

Yuexiang Wang1, Jonathan A Fletcher.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26101897      PMCID： PMC4613538          DOI： 10.1080/15384101.2015.1064676

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  6 in total

Review 1.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

Review 2.  Exon skipping therapy for Duchenne muscular dystrophy.

Authors:  Ryszard Kole; Arthur M Krieg
Journal:  Adv Drug Deliv Rev       Date:  2015-05-14       Impact factor: 15.470

3.  Genomic index predicts clinical outcome of intermediate-risk gastrointestinal stromal tumours, providing a new inclusion criterion for imatinib adjuvant therapy.

Authors:  Lydia Lartigue; Agnès Neuville; Pauline Lagarde; Céline Brulard; Piotr Rutkowski; Paolo Dei Tos; Eva Wardelmann; Maria Debiec-Rychter; Antoine Italiano; Jean-Michel Coindre; Frédéric Chibon
Journal:  Eur J Cancer       Date:  2014-11-06       Impact factor: 9.162

4.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study.

Authors:  Sebahattin Cirak; Virginia Arechavala-Gomeza; Michela Guglieri; Lucy Feng; Silvia Torelli; Karen Anthony; Stephen Abbs; Maria Elena Garralda; John Bourke; Dominic J Wells; George Dickson; Matthew J A Wood; Steve D Wilton; Volker Straub; Ryszard Kole; Stephen B Shrewsbury; Caroline Sewry; Jennifer E Morgan; Kate Bushby; Francesco Muntoni
Journal:  Lancet       Date:  2011-07-23       Impact factor: 79.321

5.  p53 modulation as a therapeutic strategy in gastrointestinal stromal tumors.

Authors:  Joern Henze; Thomas Mühlenberg; Susanne Simon; Florian Grabellus; Brian Rubin; Georg Taeger; Martin Schuler; Juergen Treckmann; Maria Debiec-Rychter; Takahiro Taguchi; Jonathan A Fletcher; Sebastian Bauer
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240

6.  Dystrophin is a tumor suppressor in human cancers with myogenic programs.

Authors:  Yuexiang Wang; Adrian Marino-Enriquez; Richard R Bennett; Meijun Zhu; Yiping Shen; Grant Eilers; Jen-Chieh Lee; Joern Henze; Benjamin S Fletcher; Zhizhan Gu; Edward A Fox; Cristina R Antonescu; Christopher D M Fletcher; Xiangqian Guo; Chandrajit P Raut; George D Demetri; Matt van de Rijn; Tamas Ordog; Louis M Kunkel; Jonathan A Fletcher
Journal:  Nat Genet       Date:  2014-05-04       Impact factor: 38.330
  6 in total
  4 in total

1.  Preclinical model-based evaluation of Imatinib resistance induced by KIT mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST).

Authors:  Qian Zhao; Cheng Zhang; Changsong Qi; Jing Yang; Yang Chen; Sai Ge; Lin Shen; Jing Gao; Jian Li
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  The Duchenne muscular dystrophy gene and cancer.

Authors:  Leanne Jones; Michael Naidoo; Lee R Machado; Karen Anthony
Journal:  Cell Oncol (Dordr)       Date:  2020-11-14       Impact factor: 6.730

Review 3.  Genetic progression in gastrointestinal stromal tumors: mechanisms and molecular interventions.

Authors:  Ke Li; Haibo Cheng; Zhang Li; Yuzhi Pang; Xiaona Jia; Feifei Xie; Guohong Hu; Qingping Cai; Yuexiang Wang
Journal:  Oncotarget       Date:  2017-03-08

4.  Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Authors:  Michael C Heinrich; Janice Patterson; Jonathan A Fletcher; Sebastian Bauer; Carol Beadling; Yuexiang Wang; Maria Debiec-Rychter; Barbara Dewaele; Christopher L Corless; Anette Duensing; Chandrajit P Raut; Brian Rubin; Tamas Ordog; Matt van de Rijn; Jerry Call; Thomas Mühlenberg
Journal:  Clin Sarcoma Res       Date:  2019-03-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.